Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alipogene tiparvovec

Next Previous
X
Search
Drug Profile

Alipogene tiparvovec

Alternative Names: AMT-010; AMT-011; AMT-11; Glybera; LPL gene therapy - AMT

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amsterdam Molecular Therapeutics
  • Developer Chiesi Farmaceutici; uniQure
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action Gene transference; Lipoprotein lipase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type I
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipoproteinaemia type I
  • Discontinued Hyperlipoproteinaemia type V

Most Recent Events

  • 09 May 2019 C3J Therapeutics has merged with AmpliPhi Biosciences Corporation to form Armata Pharmaceuticals
  • 22 Sep 2017 Discontinued - Phase-I/II for Hyperlipoproteinaemia type V in European Union (IM), because there have been no recent reports on development in this indication
  • 21 Sep 2017 Discontinued - Phase-II/III for Hyperlipoproteinaemia type I in Canada (IM), because not listed in uniQure pipeline, September 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top